1-20 of 1593 Search Results for

production

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
×Close Modal
Sort by
Image
Published: 01 December 2013
Figure 6 Production Function: Health Benefits to the Population with Eating Disorders at Different Levels of Expenditure Note: The seven “triangles” correspond to the seven assessed services in order of their value-formoney (starting fromthe origin of the graph) (1) university eating disorder More
Image
Published: 01 December 2013
Figure 7 Estimated Production Function Following the Potential Resource Reallocation Detailed in Table 3 Figure 7. Estimated Production Function Following the Potential Resource Reallocation Detailed in Table 3 More
Image
Published: 01 April 2016
Figure A2 Map of States with Mandated Production of Written Informed Consent Materials Notes : Dark gray states mandate the production of informed consent materials. States coded in light gray (IN, MS) did not have materials available at the time of this study. Figure A2. Map of States with More
Journal Article
Journal of Health Politics, Policy and Law (1 August 2014) 39 (4): 751–780.
Published: 01 August 2014
... and the economy, the FDA and other executive agencies receive input from the executive branch, the public, and in some cases, the courts, during the process of rulemaking. In this article, we examine the life cycle of FDA regulations concerning medical products and review notable features of the...
Journal Article
Journal of Health Politics, Policy and Law (1 August 2017) 42 (4): 645–666.
Published: 01 August 2017
... credibility of the evidence presented by both supporters and opponents of regulation. It also describes the final deeming rule, published in May 2016, and the FDA's response to the evidence submitted. This is the first study to examine public comments submitted to the FDA's Center for Tobacco Products, and it...
Journal Article
Journal of Health Politics, Policy and Law (1 June 1986) 11 (3): 367–392.
Published: 01 June 1986
... promotion of tobacco products. The proposal raises complex issues, ranging from determination of the effects of tobacco promotion to assessment of the constitutionality of banning advertising of a legal product. We identify the issues that underlie the concern of health professionals, review evidence...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2009) 34 (6): 863–898.
Published: 01 December 2009
... Economics 27 : 1060 -1077. Federalism and Technological Change in Blood Products Mark Zachary Taylor Georgia Institute of Technology Abstract  Recent...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2009) 34 (6): 1035–1077.
Published: 01 December 2009
...Stephen D. Sugarman This article offers a bold new idea for confronting the staggering level of death, injury, and disease caused by five consumer products: cigarettes, alcohol, guns, junk food, and motor vehicles. Business leaders try to frame these negative outcomes as “collateral damage” that is...
Journal Article
Journal of Health Politics, Policy and Law (1 October 2002) 27 (5): 860–862.
Published: 01 October 2002
...Daniel M. Fox David M. Cutler and Ernst R. Berndt, eds. Medical Care Output and Productivity. NBER Studies in Income and Wealth, volume 62. Chicago:University of Chicago Press, 2001. 611 pp. $80.00 cloth. © 2002 by Duke University Press 2002...
Journal Article
Journal of Health Politics, Policy and Law (1 June 1980) 5 (3): 470–497.
Published: 01 June 1980
... high level of quality and productivity. Moreover, the gap between the physician/NHP substitution ratio and the NHP/physician cost ratio seems wide enough to assure cost savings when NHPs are used well. Copyright © 1980 by the Dept. of Health Administration, Duke University 1980 New Health...
Image
Published: 01 August 2017
Figure 1 Pathways for Introduction of Novel or Altered Products under the FSPTCA Note : For products claiming modified or reduced risk, a separate pathway exists under section 911. Figure 1. Pathways for Introduction of Novel or Altered Products under the FSPTCA. / Note: For products More
Journal Article
Journal of Health Politics, Policy and Law (1 August 2017) 42 (4): 607–644.
Published: 01 August 2017
...Figure 1 Pathways for Introduction of Novel or Altered Products under the FSPTCA Note : For products claiming modified or reduced risk, a separate pathway exists under section 911. Figure 1. Pathways for Introduction of Novel or Altered Products under the FSPTCA. / Note: For products...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2017) 42 (6): 1099–1112.
Published: 01 December 2017
... versus tobacco/nicotine harm reduction for minors. Protecting youth from tobacco is critical, especially since tobacco/nicotine products are legal for adults, who usually begin using when young. Although cigarettes and other combustibles are the deadliest tobacco products, other products such as...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2002) 27 (6): 977–1000.
Published: 01 December 2002
...Ann Boulis; Susan Goold; Peter A. Ubel In fall 1997, a shortage of intravenous immunoglobulin (IVIG) developed in the United States because of increased demand for the product, reduced supply,and product recalls. This shortage is a useful model for understanding how our health care system responds...
Journal Article
Journal of Health Politics, Policy and Law (1 April 2001) 26 (2): 291–326.
Published: 01 April 2001
... must look at other areas of the law to assess potential MCO liability for applying CEA. In general negligence cases, courts rely on a risk-benefit test to determine customary practice. Likewise, in product liability cases, courts use a risk-utility calculus to determine liability for product design...
Journal Article
Journal of Health Politics, Policy and Law (1 August 1995) 20 (4): 973–1000.
Published: 01 August 1995
..., despite several recent interruptions in vaccine production and supply. Moreover, the increasing producer concentration in the U.S. and global vaccine industries raises the possibility that more and more important vaccines will be produced by a single firm, often in a single production facility. Is a...
Journal Article
Journal of Health Politics, Policy and Law (1 June 1981) 6 (3): 542–557.
Published: 01 June 1981
..., advantages to younger and minority workers, economy for employers, greater productivity, and, in certain industries, greater public safety. Major arguments against include: adverse effect on physical and mental health of many employees, inordinate cost to society–both in terms of pensions and loss of...
Journal Article
Journal of Health Politics, Policy and Law (1 February 1982) 7 (1): 254–270.
Published: 01 February 1982
... system as a whole, attempts to manage costs will be limited in effectiveness. The hospital is the end product of an uncontrolled system, a product that displays little understanding of the economic principles of trade-off, efficiency, and productivity. To limit spending in the hospital care system...
Journal Article
Journal of Health Politics, Policy and Law (1 April 2014) 39 (2): 417–440.
Published: 01 April 2014
... controls, greater patient cost sharing, and changes to physician incentives — all have substantial weaknesses. This article proposes a new paradigm for rationalizing health care expenditures called “relative value health insurance,” a product that would enable consumers to purchase health insurance that...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2014) 39 (3): 691–705.
Published: 01 June 2014
... political and regulatory environment, this report explores pharmaceutical pricing options for Russia that balance greater access to medicines with achieving government plans of boosting local pharmaceutical production. To match innovative medicine prices with their health benefits, in the long run, we...